MedTrace Logo

Inhaled Ibuprofen to Treat COVID-19

NCT04382768 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-06-11

No results posted yet for this study

Summary

The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.

Conditions

  • Coronavirus Infection
  • Respiratory Disease
  • SARS (Disease)

Interventions

DRUG

Inhaled Hypertonic ibuprofen

Standard of care plus lipid ibuprofen 50mg tid

Sponsors & Collaborators

  • National Council of Scientific and Technical Research, Argentina

    collaborator OTHER_GOV

  • Centro de Excelencia en Productos y Procesos Córdoba

    collaborator UNKNOWN

  • Química Luar SRL

    lead INDUSTRY

Principal Investigators

  • Dante M Beltramo, PhD · Centro de Excelencia en Productos y Procesos Córdoba

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382768 on ClinicalTrials.gov